Spots Global Cancer Trial Database for Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours
Official Title: An Open-label, Multi-centre Phase I Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours
Study ID: NCT02042781
Conditions
Interventions
Study Description
Brief Summary: This Phase Ia study aims to establish the maximum tolerated dose of once-weekly IV infused PG545 and to evaluate its safety in subjects with advanced solid tumours. In addition, the study will explore whether PG545 exposure results in changes to chemicals produced by the body that are associated with cancer growth and spread.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Nucleus Network Ltd, Melbourne, Victoria, Australia
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
Contact Details
Name: Michael Millward, MBBS
Affiliation: Sir Charles Gairdner Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
